Radium 223 Dichloride (Xofigo)®

Common name: Radium 223 Dichloride
Brand name: Xofigo®
 

What is Radium 223 Dichloride?


Radium 223 Dichloride is a radiopharmaceutical that is used to treat patients with castration-resistant prostate cancer which has spread to the bones, but has not spread to other organs in the body.
 

How is Radium 223 Dichloride administered?


Radium 223 Dichloride is administered by injection.
 

What are possible side effects of this treatment?


Everyone responds differently to treatments for bone metastases – some experience many side effects while others experience very few. Below are the most common side effects experienced by those who received radium 223 dichloride. Tell your health care team about side-effects you are experiencing so they know how best to help you manage them.
  • Nausea
  • Diarrhea
  • Vomiting
  • Swelling of the arms or legs
  • Low blood cell count
 

Is Radium 223 Dichloride covered in my province or territory?

Radium 223 Dichloride is covered by provincial drug programs in:
 
  • British Columbia (special authorization)
  • Ontario
 
Radium 223 Dichloride is not covered by provincial drug programs in:
 
  • Alberta
  • Manitoba
  • New Brunswick
  • Newfoundland & Labrador
  • Nova Scotia
  • Prince Edward Island
  • Quebec
  • Saskatchewan
  • Nunavut
  • Northwest Territories
  • Yukon
 
Last Reviewed: March 2015




Subscribe to our free monthly e-newsletter!

* indicates required

 





 
PCC Spotlight
12 innovative Canadian prostate cancer researchers set out to make new Discoveries

Toronto, ON – September 28, 2017: 12 forward-thinking Canadian prostate cancer researchers have been rewarded for their innovation with Movember Discovery Grants.
More

Gray Tools '2017 Together We Are Stronger' campaign a success in creating awareness and raising funds for prostate cancer

BRAMPTON, Ontario, Sept 26, 2017 (GLOBE NEWSWIRE) -- Gray Tools Canada Inc, in cooperation with Prostate Cancer Canada, is proud to announce that its “2017 Together We Are Stronger” initiative raised $4,000, which will go directly towards funding valuable research that is needed to improve the way we diagnose, treat, and support men living with the disease.
More

Rocco Rossi to wrap up successful 5-year tenure as Prostate Cancer Canada CEO

September 7, 2017 - TORONTO, ON - With mixed emotions, longstanding Prostate Cancer Canada (PCC) President and CEO, Rocco Rossi, formally announced today that his time leading the organization will officially come to a close as of December 31, 2017.
More


Click here for news archive